Pathogen Inactivation of Platelet and Plasma Blood Components for Transfusion Using the INTERCEPT Blood SystemTM

@article{Irsch2011PathogenIO,
  title={Pathogen Inactivation of Platelet and Plasma Blood Components for Transfusion Using the INTERCEPT Blood SystemTM},
  author={Johannes Irsch and Lily Lin},
  journal={Transfusion Medicine and Hemotherapy},
  year={2011},
  volume={38},
  pages={19 - 31}
}
  • J. Irsch, Lily Lin
  • Published 27 January 2011
  • Medicine, Biology
  • Transfusion Medicine and Hemotherapy
Background: The transmission of pathogens via blood transfusion is still a major threat. [] Key Result Furthermore, it integrates well into routine blood center operations. The clinical study program demonstrates the successful use for very diverse patient groups. The hemovigilance program shows safety and tolerability in routine use. Approximately 700,000 INTERCEPT-treated products have been transfused worldwide. The system is in clinical use since class III CE-mark registration in 2002.

Figures and Tables from this paper

Pathogen Inactivation Technologies for Cellular Blood Components: an Update
  • P. Schlenke
  • Biology, Medicine
    Transfusion Medicine and Hemotherapy
  • 2014
TLDR
The invention and adaption of pathogen inactivation technologies for red blood cell units and whole blood donations suggest the universal applicability of these technologies and foster a paradigm shift in the manufacturing of safe blood.
Pathogen reduction of blood components and plasma derivatives
TLDR
This chapter discusses the PRTs that are commonly used or under development for the various product classes: (1) labile blood components (whole blood, platelets, or FFP); (2) manufactured pooled, solvent–detergent (S/D)-treated plasma; and (3)manufactured plasma-derived medicinal products (PDMPs) such as immunoglobulins, purified clotting factors, and albumin.
Platelet transfusion associated risks and improvement of platelet transfusion safety with Amotosalen/UVA pathogen inactivation technology
TLDR
Long-term routine clinical experience, also with children and neonates, shows the safety and efficacy of INTERCEPT platelet transfusions, and national hemovigilance data of Switzerland, France and Belgium show an improved clinical outcome in the acute as well as in the prophylactic setting with a significant decrease in septic and other non-hemolytic transfusion reactions.
The long and winding road to pathogen reduction of platelets, red blood cells and whole blood
  • P. Rebulla
  • Medicine, Biology
    British journal of haematology
  • 2019
TLDR
This review summarizes pre‐clinical investigations and selected outcomes from clinical trials using the above PRTs and suggests further studies are warranted to decrease cell storage lesions after PRT treatment and to test PRTs in different medical and surgical conditions.
Pathogen reduction technologies: The pros and cons for platelet transfusion
TLDR
The literature regarding PRTs is reviewed, the advantages and disadvantages related to their application in platelet transfusion medicine are presented, and the safety of PRT-treated platelets is questioned.
Pathogen Reduction for Platelets—A Review of Recent Implementation Strategies
TLDR
Overall, the reviewed studies show that significant progress has been made in PRT implementation, although additional efforts will be necessary to reduce the storage lesion of PRT platelets and to expand the sustainable applicability ofPRT to all labile blood components.
Preparation and pathogen inactivation of double dose buffy coat platelet products using the INTERCEPT blood system.
TLDR
A novel method for preparing double dose whole blood derived platelet concentrates from pools of 7 buffy coats and subsequently treating the double dose units with the INTERCEPT Blood System for pathogen inactivation is presented.
Update on pathogen inactivation treatment of plasma, with the INTERCEPT Blood System: Current position on methodological, clinical and regulatory aspects.
  • J. Irsch, J. Seghatchian
  • Medicine
    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • 2015
Pathogen Inactivation of Cellular Blood Products—An Additional Safety Layer in Transfusion Medicine
TLDR
The relevance of PI for the field of transfusion medicine is discussed and the available and emerging PI technologies that can be used to treat cellular blood products such as platelet and red blood cell units are described.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 77 REFERENCES
Protecting the blood supply from emerging pathogens: the role of pathogen inactivation.
  • M. Blajchman
  • Biology
    Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine
  • 2009
Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial.
TLDR
Platelet components prepared with PCT offer the potential to further improve the safety of platelet transfusion using technology compatible with current methods to prepare buffy coat platelet components.
Concerning Caspari et al: Pathogen Inactivation of Cellular Blood Products – More Security for the Patient or Less? Transfus Med Hemother 2003;30:261–263
TLDR
With the recent CE Mark approval of the INTERCEPT Blood System for Platelets and its introduction into European blood centers, it is relevant to re-consider the issues raised by Caspari et al. regarding pathogen inactivation of cellular blood products.
The role of the plasma from platelet concentrates in transfusion reactions.
TLDR
Bioreactive substances in the plasma supernatant of the platelet product cause most febrile reactions associated with platelet transfusions, and removing the plasmasupernatant before transfusion can minimize or prevent these reactions.
Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease
TLDR
This mini review focuses on the salient aspects of current and evolving technology for prevention of TA-GVHD, a serious complication of blood component transfusion therapy.
Photochemical Inactivation of Bacteria and HIV in Buffy–Coat–Derived Platelet Concentrates under Conditions That Preserve in vitro Platelet Function
TLDR
PCT with 150 μM S–59 and a 3 J/cm2 UVA treatment does not adversely affect in vitro properties of BC PCs stored at 22°C for 7 days, extending the earlier reported efficacy of PCT apheresis PCs to BC PCs.
Pathogen inactivation: making decisions about new technologies
Methods to remove and inactivate pathogens, used extensively in the manufacture of plasma protein fractions, have all but eliminated transmission of infectious agents by these products. 1
Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use
TLDR
Utilization of platelet components (PCs) and red blood cell (RBC) components was analyzed for 3 years before and 3 years after introduction of pathogen inactivation to assess the impact of pathogenic inactivation on component use.
...
1
2
3
4
5
...